Globavir Biosciences

Globavir, founded in 2011 by Dr. Shalabh Gupta, focuses on developing therapeutics and diagnostics for infectious diseases. The company leverages multiple licenses from Stanford University to advance its research and product development. Globavir acquired BioCycive in 2014, integrating it as a wholly owned subsidiary. This acquisition allowed Globavir to expand its capabilities, leading to a partnership in 2015 with Sorrento Therapeutics to advance BioCycive's lead program. Additionally, in 2016, Globavir collaborated with Bio-Rad to enhance its diagnostic test offerings. The company addresses a range of infectious diseases, including dengue, West Nile, chikungunya, and Ebola, while also extending its research efforts into cancer treatment.